Loading...
Market
What will be PTC518's US market share in Huntington's disease treatments by 2026?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Industry reports and market analysis
Story
PTC Therapeutics and Novartis Partner on $2.9 Billion Huntington's Disease Drug Deal with $1 Billion Upfront
Dec 2, 2024, 12:04 PM
PTC Therapeutics has entered into a global license and collaboration agreement with Novartis for the development of PTC518, an experimental drug targeting Huntington's disease. Under the terms of the deal, PTC Therapeutics will receive $1 billion in cash upfront. Additionally, the companies will share U.S. profits and losses on a 40/60 basis, with PTC receiving 40% and Novartis 60%. The total value of the agreement could reach up to $2.9 billion, contingent on milestone achievements. This collaboration represents a significant step in advancing the development of PTC518, which addresses a rare neurological disorder.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
United States only • 25%
United States and European Union • 25%
United States, European Union, and Japan • 25%
Other combinations or none • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%